MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Cash and Cash Equivalents 2011-2026 | ARAV
Annual Cash and Cash Equivalents Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.7 M | 59.4 M | 60.5 M | 65.1 M | 57 M | 81.1 M | 201 M | 182 M | 171 M | 13.3 M | 404 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 201 M | 404 K | 85.9 M |
Quarterly Cash and Cash Equivalents Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.54 M | 18.4 M | 35.9 M | 53.7 M | 27.9 M | 46.8 M | 65.8 M | 59.4 M | 67.5 M | 75.4 M | 78.7 M | 60.5 M | 60.5 M | 60.5 M | 60.5 M | 65.1 M | 65.1 M | 65.1 M | 65.1 M | 57 M | 57 M | 57 M | 57 M | 81.1 M | 81.1 M | 81.1 M | 81.1 M | 201 M | 201 M | 201 M | 201 M | 182 M | 182 M | 182 M | 182 M | 171 M | 171 M | 171 M | 171 M | 13.3 M | 13.3 M | 13.3 M | 13.2 M | 404 K | - | - | - | 950 K | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 201 M | 404 K | 85.8 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
1.91 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
261 K | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 16.88 | -2.43 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 2.79 | -8.09 % | $ 261 M |  Israel |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
5.71 B | - | - | $ 96.9 B |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
231 M | $ 7.56 | -3.45 % | $ 207 M | Israel |
 |
Athira Pharma
ATHA
|
69.3 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
54 M | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
6.38 M | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
482 M | $ 50.41 | -1.36 % | $ 13.7 B | USA |
 |
Fortress Biotech
FBIO
|
79.4 M | $ 2.43 | 5.65 % | $ 67.8 M | USA |
 |
Midatech Pharma plc
MTP
|
8.53 M | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
77 M | $ 23.1 | -3.57 % | $ 299 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
36.8 M | $ 9.76 | 5.63 % | $ 279 M | USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
104 M | $ 1.59 | - | $ 423 M | Britain |
 |
BioNTech SE
BNTX
|
7.68 B | $ 89.16 | -3.08 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
50.7 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
17.7 M | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
7.56 B | $ 130.07 | -1.51 % | $ 162 B | USA |
 |
Genmab A/S
GMAB
|
3.55 B | $ 26.8 | -0.37 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
5.53 M | $ 3.41 | -2.25 % | $ 5.61 M | Israel |
 |
Aeterna Zentaris
AEZS
|
7.31 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 7.74 | -0.64 % | $ 5.26 B |  Spain |
 |
AIkido Pharma
AIKI
|
34 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
5.67 M | $ 0.72 | -1.05 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 29.69 | -0.92 % | $ 799 M | USA |
 |
Aptose Biosciences
APTO
|
935 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
98.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
42.9 M | $ 21.51 | -0.3 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |